Tesi and Debiopharm in $10m series-B for BC Platforms

Debiopharm was the lead investor in the round, with the VC firm and existing investors also providing capital.

BC Platforms will use the new money to launch new technologies and integrate clinical and genomic data. It will also expand its data management software business worldwide.

Previous funding
The company has a Finnish background but recently moved its headquarters to Switzerland. This is the first funding round for the Swiss-Finnish entity but the company had raised funds from private investors when its operations were purely Finland-based.

Company
Founded in 1997 and based in Basel, BC Platforms is a genomic data management company. It provides platforms for the integration of genomic and clinical data to more than 50 international institutions in 19 countries. The company employs a staff of around 30 and generated revenues of €2m in 2016.

People
Tesi – Joni Karsikas (investment manager).
Debiopharm – Tanja Dowe (head of innovation fund).
BC Platforms – Tero Silvola (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Technology
• Early-stage
• Switzerland
• Finland
• Venture